- Details
- Ashish Kamat and Yair Lotan discuss an innovative AI-based assessment tool presented by Valar Labs, aimed at refining the management of BCG-unresponsive bladder cancer. Dr. Lotan discusses the tool's capability to enhance the precision of prognosis and treatment strategies by analyzing pathologic slides with AI to identify high-risk patients who might not respond well to BCG treatment. This AI alg...
|
- Details
- Pat Hensley hosts a discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle invasive bladder cancer. Joining him are Dr. Seth Lerner and Dr. Sia (Siamak) Daneshmand, who contribute their insights on the evolution of surgical guidelines and the integration of new biomarkers in the treatment of advanced bladder cancer. Dr. Lerner elaborates on the standard and extended...
|
- Details
- Ashish Kamat discusses the controversial topic of repeat transurethral resection (reTUR) for high-grade non-muscle-invasive bladder cancer with Badrinath (Badri) Konety and Jeremy Teoh. Dr. Konety highlights the importance of surgeon expertise, noting that experience significantly impacts the quality of the initial TUR. Dr. Teoh emphasizes the need for proper training to avoid the necessity of reT...
|
- Details
- Zach Klaassen hosts Stephen B Williams to discuss an innovative AI biomarker for non-muscle invasive bladder cancer. Dr. Williams emphasizes the significance of refining clinical predictors for bladder cancer, highlighting the potential of the AI biomarker to revolutionize treatment approaches. This tool, developed by Valar Labs using data from over 300,000 specimens, aids in distinguishing betwee...
|
- Details
- Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer. Dr. Tay discusses the precision and reduced toxicity offered by focal therapy, which targets only cancerous tissues within the prostate, sparing non-cancerous areas. He highlights various treatment modalities including cryotherapy, HIFU, and newer methods like irreversible electroporat...
|
- Details
- Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate AI test, highlighting its use in identifying biochemical recurrence after prostatectomy. This AI model, validated with data from key trials, not only distinguishes patients based on the aggressiveness of their disease but...
|
- Details
- Zach Klaassen discusses with Todd Morgan about innovative post-prostatectomy biomarkers. Dr. Morgan presents findings on a new AI model developed by ArteraAI for assessing biochemical recurrence in prostate cancer patients post-prostatectomy. This model, validated using clinical data and digital pathology from two significant trials, shows high predictive accuracy. It aims to distinguish patients...
|
- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
- Details
- Sam Chang hosts Rob Svatek who discusses the PIVOT-006 trial. This phase three trial targets intermediate-risk, non-muscle invasive bladder cancer, comparing a novel therapy, Cretostimogene grenadenorepvec (Creto), against observation. The goal is to enroll 364 patients over 30 months to demonstrate a 10% improvement in recurrence-free survival. The trial focuses on patients who do not qualify as...
|
